Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Generalized anxiety disorder (GAD) is one of the most common psychiatric disorders associated with substantial dysfunction and socioeconomic burden. Pharmacotherapy is the first choice for GAD. Remission [Hamilton Anxiety Scale (HAM-A) score ≤7] is regarded as a crucial treatment goal for patients with GAD. There is no up-to-date evidence to compare remission rate and tolerability of all available drugs by using network meta-analysis. Therefore, the goal of our study is to update evidence and determine the best advantageous drugs for GAD in remission rate and tolerability profiles. Method: We performed a systematic review and network meta-analysis of double-blind randomized controlled trials (RCTs). We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, wanfang data, China Biology Medicine and ClinicalTrials.gov from their inception to March 2020 to identify eligible double-blind, RCTs reporting the outcome of remission in adult patients who received any pharmacological treatment for GAD. Two reviewers independently assessed quality of included studies utilizing the Cochrane Collaboration’s risk of bias tool as described in Cochrane Collaboration Handbook and extracted data from all manuscripts. Our outcomes were remission rate (proportion of participants with a final score of seven or less on HAM-A) and tolerability (treatments discontinuations due to adverse events). We calculated summary odds ratios (ORs) and 95% confidence intervals (CIs) of each outcome via pairwise and network meta-analysis with random effects. Results: Overall, 30 studies were included, comprising 32 double-blind RCTs, involving 13,338 participants diagnosed as GAD by DSM-IV criteria. Twenty-eight trials were rated as moderate risk of bias, four trials as low. For remission rate, agomelatine (OR 2.70, 95% CI 1.74–4.19), duloxetine (OR 1.88, 95% CI 1.47–2.40), escitalopram (OR 2.03, 95% CI 1.48–2.78), paroxetine (OR 1.74, 95% CI 1.25–2.42), quetiapine (OR 1.88, 95% CI 1.39–2.55), and venlafaxine (OR 2.28, 95% CI 1.69–3.07) were superior to placebo. For tolerability, sertraline, agomelatine, vortioxetine, and pregabalin were found to be comparable to placebo. However, the others were worse than placebo in terms of tolerability, with ORs ranging between 1.86 (95% CI 1.25–2.75) for tiagabine and 5.98 (95% CI 2.41–14.87) for lorazepam. In head-to-head comparisons, agomelatine, duloxetine, escitalopram, quetiapine, and venlafaxine were more efficacious than tiagabine in terms of remission rate, ORs from 1.66 (95% CI 1.04–2.65) for duloxetine to 2.38 (95% CI 1.32–4.31) for agomelatine. We also found that agomelatine (OR 2.08, 95% CI 1.15–3.75) and venlafaxine (OR 1.76, 95% CI 1.08–2.86) were superior to vortioxetine. Lorazepam and quetiapine were poorly tolerated when compared with other drugs. Conclusions: Of these interventions, only agomelatine manifested better remission with relatively good tolerability but these results were limited by small sample sizes. Duloxetine, escitalopram, venlafaxine, paroxetine, and quetiapine showed better remission but were poorly tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · cited 1×
“The surface under the cumulative ranking curve (SUCRA) and the mean ranks were calculated to rank the treatments for each outcome (Salanti et al., 2011).”
MethodCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473 · cited 1×
“A frequentist framework was applied to combine evidence from direct and indirect comparisons with a random effects model (Chaimani et al., 2013).”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“Loop inconsistency was assessed in every closed triangular or quadratic loop via the “loopspecific” approach, wherein a 95% CI excluding zero suggests that the loop is inconsistent (Higgins et al., 2012; Li et al., 2017).”
MethodSize and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Chaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521 · cited 1×
“The comparison-adjusted funnel plots were generated to investigate whether there are study-small effects in the intervention network (Chaimani and Salanti, 2012).”
MethodTyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
Research works printed but not linked: 46
- Alaka, 2014, Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial, Int. J. Geriatr. Psychiatr., 29, 978, 10.1002/gps.4088 · DOI · Paper page
- Allgulander, 2004, Efficacy of sertraline in a 12-week trial for generalized anxiety disorder, Am. J. Psychiatr., 161, 1642, 10.1176/appi.ajp.161.9.1642 · DOI · Paper page
- Baldwin, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ, 342, d1199, 10.1136/bmj.d1199 · DOI · Paper page
- Baldwin, 2011, Evidence-based pharmacological treatment of generalized anxiety disorder, Int. J. Neuropsychopharmacol., 14, 697, 10.1017/s1461145710001434 · DOI · Paper page
- Ball, 2015, Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder, Int. Psychogeriatr., 27, 1533, 10.1017/s1041610215000381 · DOI
- Bidzan, 2012, Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial, Eur. Neuropsychopharmacol, 22, 847, 10.1016/j.euroneuro.2012.07.012 · DOI
- Bose, 2008, Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder, Depress. Anxiety, 2, 854, 10.1002/da.20355 · DOI · Paper page
- Boyer, 2004, Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release, Eur. Psychiatr., 19, 272, 10.1016/j.eurpsy.2004.05.010 · DOI
- Coric, 2010, Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder, Depress. Anxiety, 27, 417, 10.1002/da.20695 · DOI · Paper page
- Davidson, 2004, Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study, Depress. Anxiety, 19, 234, 10.1002/da.10146 · DOI · Paper page
- Doyle, 2003, Establishment of remission criteria for anxiety disorders, J. Clin. Psychiatr., 40
- Feltner, 2003, A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 23, 240, 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
- Freiesleben, 2015, A systematic review of agomelatine-induced liver injury, J. Mol. Psychiatry, 3, 4, 10.1186/s40303-015-0011-7 · DOI · Paper page
- Guardiola-Lemaitre, 2014, Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties, Br. J. Pharmacol., 171, 3604, 10.1111/bph.12720 · DOI · Paper page
- Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/yic.0b013e32807fb1b2 · DOI · Paper page
- He, 2019, Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis, J. Psychiatr. Res., 118, 21, 10.1016/j.jpsychires.2019.08.009 · DOI · Paper page
- Higgins, 2011, The Cochrane collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
- Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of Health Care interventions: checklist and explanations, Ann. Intern. Med., 162, 777, 10.7326/m14-2385 · DOI · Paper page
- Kasper, 2014, Lavender oil preparation silexan is effective in generalized anxiety disorder–a randomized, double-blind comparison to placebo and paroxetine, Int. J. Neuropsychopharmacol., 17, 859, 10.1017/s1461145714000017 · DOI · Paper page
- Khan, 2011, A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 31, 418, 10.1097/jcp.0b013e318224864d · DOI · Paper page
- Koponen, 2007, Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary Care physicians, Prim. Care Companion J. Clin. Psychiatry, 9, 100, 10.4088/pcc.v09n0203 · DOI · Paper page
- Laporte, 2017, Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies, Pharmacol. Res., 118, 19, 10.1016/j.phrs.2016.08.017 · DOI · Paper page
- Lenox-Smith, 2003, A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary Care, Br. J. Gen. Pract., 53, 772
- Li, 2017, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose Co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials, Diabetes Obes. Metabol., 19, 348, 10.1111/dom.12825 · DOI · Paper page
- Mahableshwarkar, 2014, A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder, Int. J. Clin. Pract., 68, 49, 10.1111/ijcp.12328 · DOI · Paper page
- Mandos, 2009, Achieving remission in generalized anxiety disorder. What are the treatment options?, Psychiatr. Times, 26, 38
- Maneeton, 2016, Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials, Drug Des. Devel. Ther., 10, 259, 10.2147/dddt.s89485 · DOI · Paper page
- Merideth, 2012, Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study, Int. Clin. Psychopharmacol., 27, 40, 10.1097/yic.0b013e32834d9f49 · DOI · Paper page
- Mezhebovsky, 2013, Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder, Int. J. Geriatr. Psychiatr., 28, 615, 10.1002/gps.3867 · DOI · Paper page
- Millan, 2003, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways, J. Pharmacol. Exp. Ther., 306, 954, 10.1124/jpet.103.051797 · DOI · Paper page
- Montgomery, 2008, Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder, Br. J. Psychiatry, 193, 389, 10.1192/bjp.bp.107.037788 · DOI · Paper page
- Nicolini, 2009, Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial, Psychol. Med., 39, 267, 10.1017/s0033291708003401 · DOI · Paper page
- Nimatoudis, 2004, Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study, Int. Clin. Psychopharmacol., 19, 331, 10.1097/00004850-200411000-00003 · DOI · Paper page
- Pollack, Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint, J. Psychiatr. Res., 42, 1176, 10.1016/j.jpsychires.2008.02.002 · DOI
- Pollack, Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies, J. Clin. Psychopharmacol., 28, 308, 10.1097/jcp.0b013e318172b45f · DOI · Paper page
- Pollack, 2001, Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial, J. Clin. Psychiatr., 62, 350, 10.4088/jcp.v62n0508 · DOI · Paper page
- Qin, 2019, Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes, BMJ Open, 9, e033161, 10.1136/bmjopen-2019-033161 · DOI
- Rickels, 2003, Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study, Am. J. Psychiatry, 160, 749, 10.1176/appi.ajp.160.4.749 · DOI · Paper page
- Rothschild, 2012, Vortioxetine (Lu AA21004) 5 Mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur. Neuropsychopharmacol, 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
- Rynn, 2008, Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial, Depress. Anxiety, 25, 182, 10.1002/da.20271 · DOI · Paper page
- Stack, 2013, Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example, Ann. Intern. Med., 159, 285, 10.7326/0003-4819-159-4-201308200-00009 · DOI
- Stein, 2008, Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 28, 561, 10.1097/jcp.0b013e318184ff5b · DOI · Paper page
- Stein, 2011, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies, Hum. Psychopharmacol. Clin. Exp., 26, 614, 10.1002/hup.1256 · DOI
- Stein, 2017, Efficacy and safety of agomelatine (10 or 25 Mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study, Eur. Neuropsychopharmacol, 27, 526, 10.1016/j.euroneuro.2017.02.007 · DOI · Paper page
- Wu, 2011, Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China, Chin. Med. J., 124, 3260, 10.3760/cma.j.issn.0366-6999.2011.20.010 · doi:10.3760/cma.j.issn.0366-6999.2011.20.010
Cited by
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., McCloud, T., Goble, T., Rodriguez-Sanchez, J., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286773 · Cited by 3
“…disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et al., 2016; Blanco et al., 2013; Kong et al., 2020; Stahl and Li, 2003).”
Background
Metadata
- Authors
- Kong, W., Deng, H., Wan, J., Zhou, Y., Zhou, Y., Song, B., & Wang, X.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-11
- Volume
- 11
- Pages
- 580858-580858
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3103418528
- Cited by
- 44
- References
- 15
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.